There is no doubt that patients who continue maintenance Revlimid (lenalidomide) following autologous transplant do better than those who do not. Dr. Phil McCarthy showed unequivocally in CALGB 100104 (Revlimid vs placebo) that progression free survival (PFS) and overall survival (OS) are longer for patients taking maintenance Revlimid. Likewise, maintenance therapy extends PFS for patients […]
The life expectancy of standard-risk myeloma patients has increased significantly in the last decade, thanks to novel therapies. Some trials that are in progress, such as the MAIA trial comparing Revilmid and dexamethasone (Rd) versus Daratumumab, Revilmid and dexamethasone (DRd) have not yet met their progression-free survival (PFS) end state and are at more than […]
It is hard to know what to expect from this year’s American Society of Hematology (ASH) meeting. The 62nd Annual Meeting & Exposition was to be held in San Diego, probably my most favorite location for this meeting. The weather is most often warm, especially compared to Rochester, MN, and the atmosphere is filled with […]
